ABSTRACT
INTRODUCTION: Treatment with lithium can cause several neurological side effects, even at therapeutic levels. CASE REPORT: We report the case of a 49-year-old woman, with bipolar disorder and depression, undergoing treatment with lithium, antidepressants and antipsychotics, who was admitted to hospital due to a clinical picture of visual hallucinations with an elevated lithaemia of 2.1 mEq/L (therapeutic range: 0.6-1.2 mEq/L). The patient developed a severe encephalopathy that required the use of assisted ventilation in the intensive care unit. Initial magnetic resonance imaging showed a reversible bilateral symmetrical hyperintensity in the dentate nuclei in T2 and T2-FLAIR sequences. Over the following months she gradually developed a pancerebellar syndrome with evidence of a marked loss of bilateral volume in the cerebellum, above all at the expense of the vermis, which was accompanied by a permanent and disabling cerebellar syndrome. CONCLUSIONS: Although treatment with lithium can cause a variety of neurological side effects, they are usually reversible. However, they occasionally give rise to permanent and disabling sequelae, as in the case of the patient reported here, with a marked and progressive cerebellar atrophy, accompanied by permanent sequelae in the form of a disabling cerebellar syndrome. The cerebellar neurotoxicity of lithium must be taken into account in the broad differential diagnosis of cerebellar ataxia in adults.
TITLE: Alteraciones reversibles en los nucleos dentados y atrofia cerebral de rapida instauracion debido a neurotoxicidad por litio.Introduccion. El tratamiento con litio puede ocasionar diversos efectos adversos neurologicos, incluso con niveles terapeuticos. Caso clinico. Mujer de 49 años, con trastorno bipolar y depresion, en tratamiento con litio, antidepresivos y antipsicoticos, que ingreso por un cuadro de alucinaciones visuales con una litemia elevada de 2,1 mEq/L (rango terapeutico: 0,6-1,2 mEq/L). Progreso a una encefalopatia grave que requirio asistencia respiratoria en la unidad de cuidados intensivos. La resonancia magnetica cerebral inicial mostro una hiperintensidad simetrica bilateral reversible en los nucleos dentados en las secuencias T2 y T2-FLAIR. A lo largo de los meses posteriores desarrollo de forma progresiva un sindrome pancerebeloso con evidencia de una marcada perdida de volumen bilateral en el cerebelo, sobre todo a expensas del vermis, que se acompaño clinicamente de un sindrome cerebeloso permanente e invalidante. Conclusiones. Aunque el tratamiento con litio ocasiona efectos adversos neurologicos variados, estos suelen ser reversibles. Puede dar lugar a secuelas permanentes e incapacitantes, como la paciente descrita, con una atrofia cerebelosa marcada y progresiva, acompañada de secuelas permanentes en forma de sindrome cerebeloso invalidante. La neurotoxicidad cerebelosa del litio debe considerarse en el amplio diagnostico diferencial que representa la ataxia cerebelosa del adulto.
Subject(s)
Antidepressive Agents/adverse effects , Brain/drug effects , Brain/pathology , Cerebellar Nuclei/drug effects , Lithium Compounds/adverse effects , Neurotoxicity Syndromes/etiology , Atrophy/chemically induced , Female , Humans , Middle AgedABSTRACT
OBJECTIVE: Oxidative stress is implicated in Parkinson's disease (PD) and Alzheimer's disease (AD), and heme oxygenase-1 (HO-1) is a potent antioxidant overexpressed in PD substantia nigra and AD cerebral cortex and hippocampus, indicating a possible up-regulation of antioxidant defenses in both neurodegenerative diseases. The role of HO-1 in peripheral blood of PD and AD patients remains unresolved. METHODS: We measured serum HO-1 levels in 107 patients with PD, 105 patients with AD, 104 controls for PD and 120 controls for AD. RESULTS: The median serum concentration of HO-1 was significantly higher in PD patients (2.04 ng/ml) compared with that of PD controls (1.69 ng/ml, P = 0.016), with PD patients predominating over controls in the upper tertile of serum HO-1 levels, whereas there was more PD controls than PD patients in the lower tertile (P = 0.006). Median serum levels of HO-1 did not differ significantly between AD patients and AD controls. CONCLUSION: The increase of serum HO-1 levels in PD patients could indicate a systemic antioxidant reaction related to a chronic oxidative stress state in PD brain.
Subject(s)
Alzheimer Disease/blood , Heme Oxygenase-1/blood , Parkinson Disease/blood , Adult , Age Factors , Aged , Aged, 80 and over , Alzheimer Disease/drug therapy , Alzheimer Disease/genetics , Apolipoprotein E4/genetics , Female , Humans , Male , Middle Aged , Parkinson Disease/drug therapy , Severity of Illness Index , Sex Factors , Time FactorsABSTRACT
BACKGROUND: Oxidative stress is a central factor in the pathogenesis of Parkinson's disease (PD). Heme oxygenase-1 (HO-1) is an antioxidant protein expressed in response to oxidative challenge, and its expression levels are inversely correlated with glycogen synthase kinase-3beta (GSK3beta) activity. Underexpression of HO-1 in concert with an upregulation of GSK3beta would result in a less effective antioxidant response and might increase the risk of PD. METHODS: We examined two functional polymorphism in the promoter regions of HO-1 (-413, rs2071746) and GSK3beta (-157, rs6438552) in a group of 251 Spanish patients with PD and 234 controls. RESULTS: Subjects carrying both the HO-1 (-413, rs2071746) TT genotype and the GSK3beta (-157, rs6438552) TT genotype had a four times higher risk of developing PD than subjects without these genotypes (adjusted by age and sex OR = 4.12; 95% CI = 1.45-11.71; Bonferroni corrected P = 0.024). CONCLUSIONS: Considering synergistic effects between polymorphisms in oxidative stress-related genes may help in determining the risk profile for PD.
Subject(s)
Genetic Predisposition to Disease/genetics , Glycogen Synthase Kinase 3/genetics , Heme Oxygenase-1/genetics , Oxidative Stress/genetics , Parkinson Disease/enzymology , Parkinson Disease/genetics , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Gene Frequency/genetics , Genotype , Glycogen Synthase Kinase 3 beta , Humans , Male , Middle Aged , Polymorphism, Genetic/genetics , Promoter Regions, Genetic/genetics , Risk AssessmentABSTRACT
OBJECTIVE: Glycogen synthase kinase-3beta (GSK-3beta) and cyclin-dependent kinase 5 (CDK5) have been implicated as two major protein kinases involved in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles. CDK5 regulatory subunit 1 (CDK5R1) encodes for p35, a protein required for activation of CDK5. As both CDK5R1 and GSK-3beta genes are related to phosphorylation of tau, we examined the combined contribution of these genes to the susceptibility for AD. METHODS: In a case-control study in 283 AD patients and 263 healthy controls, we examined the combined effects between CDK5R1 (3'-UTR, rs735555) and GSK-3beta (-50, rs334558) polymorphisms on susceptibility to AD. RESULTS: Subjects carrying both the CDK5R1 (3'-UTR, rs735555) AA genotype and the GSK-3beta (-50, rs334558) CC genotype had a 12.5-fold decrease in AD risk (adjusted by age, sex and APOE status OR = 0.08, 95% CI = 0.01-0.76, P = 0.03), suggesting synergistic effects (epistasis) between both genes. CONCLUSION: These data support a role for tau phosphorylation regulating genes in risk for AD.
Subject(s)
Alzheimer Disease/genetics , Cyclin-Dependent Kinase 5/genetics , Epistasis, Genetic , Glycogen Synthase Kinase 3/genetics , Protein Subunits/genetics , Aged , Aged, 80 and over , Alzheimer Disease/etiology , Case-Control Studies , Female , Glycogen Synthase Kinase 3 beta , Humans , Male , Middle Aged , Phosphorylation/genetics , Risk Factors , tau Proteins/geneticsABSTRACT
OBJECTIVE: To describe the case of a young woman with the diagnosis of acute inflammatory demyelinating polyradiculoneuropathy (AIDP), who during the course of the disease developed an electrophysiologic pattern of acute motor conduction block neuropathy (AMCBN). METHODS: Electrophysiologic techniques including needle EMG, standard motor and sensory nerve conductions studies, and somatosensory evoked potentials were carried out over the four months after symptom onset. RESULTS: The results of four neurophysiological studies, performed on Days 14, 26, 35 and 125 after symptomatic onset are reported. All immunological determinations including antiganglioside antibodies (GM1, GM2, GM3, asialoGM1, GD1a, GD1b, GD3, GQ1b and GT1b) were negative. The patient had a favorable evolution following treatment with intravenous immunoglobulins (IVIg). CONCLUSIONS: We conclude that the electrophysiologic hallmark of AMCBN may occur in the course of AIDP. Serial investigation including proximal, intermediate and distal segments of all nerves from upper and lower limbs is essential for its detection.
Subject(s)
Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/physiopathology , Motor Neurons/physiology , Neural Conduction/physiology , Adult , Electrodiagnosis , Electromyography , Electrophysiology , Evoked Potentials, Somatosensory/physiology , Female , Functional Laterality/physiology , Humans , Median Nerve/physiopathology , Muscle, Skeletal/physiology , Neurologic Examination , Peroneal Nerve/physiopathology , Tibial Nerve/physiopathologyABSTRACT
A chronic inflammatory process with activation of microglial cells contribute to the neurodegeneration associated with Alzheimer's disease (AD). Estrogen could protect the brain from neurodegeneration by augmenting the secretion of the anti-inflammatory interleukin (IL)-10 from microglial cells. In a case-control study in 231 AD patients and 194 healthy controls, we examined whether the combined effects between the genes coding for aromatase (a critical enzyme in the peripheral synthesis of estrogens) and IL-10 might be responsible for susceptibility to AD. Subjects carrying both the aromatase (5 -UTR) GG and the IL-10 (-1082) GG genotypes had a six times lower risk of developing AD than subjects without these risk genotypes (OR = 0.17, 95% CI = 0.04-0.77, P = 0.02).
Subject(s)
Alzheimer Disease/genetics , Aromatase/genetics , Estrogens/biosynthesis , Genetic Predisposition to Disease/genetics , Interleukin-10/genetics , Polymorphism, Genetic/genetics , 5' Untranslated Regions/genetics , Aged , Aged, 80 and over , Alzheimer Disease/enzymology , Brain/enzymology , Brain/physiopathology , Brain Chemistry/genetics , Case-Control Studies , DNA Mutational Analysis , Female , Gene Frequency , Genetic Testing , Genetic Variation/genetics , Genotype , Humans , Male , Middle Aged , Odds RatioABSTRACT
For the first time, the multilocus approach by the set-association method has been applied for the analysis of a cluster of five genes [tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), IL-8, IL-1alpha and IL-10] involved in the brain neuroinflammatory pathway in Parkinson's disease (PD), in a well-defined group of 197 PD patients and 173 control subjects from Spain. Set-association analysis did not reveal an independent or an interactive effect of these inflammatory genes on the PD risk.
Subject(s)
Inflammation/genetics , Parkinson Disease/etiology , Parkinson Disease/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Aged , Aged, 80 and over , Brain/metabolism , Female , Genotype , Humans , Inflammation/complications , Inflammation/metabolism , Interleukin-10/genetics , Interleukin-1alpha/genetics , Interleukin-6/genetics , Interleukin-8/genetics , Male , Middle Aged , Parkinson Disease/metabolism , Parkinson Disease/pathology , Spain/epidemiology , Tumor Necrosis Factor-alpha/geneticsABSTRACT
OBJECTIVE: As transforming growth factor-beta1 (TGF-beta1) determines important neurotrophic and neuroprotective actions, we postulated serum TGF-beta1 levels could be low in Alzheimer's disease (AD), and TGF-beta1 genetic variation could be associated with AD risk through modulating serum TGF-beta1 levels. METHODS: TGF-beta1 (-800) (rs 1800468), (-509) (rs 1800469) and (+869) (rs 1982073) polymorphisms were genotyped in 412 AD patients and 406 controls. We measured serum TGF-beta1 levels (by ELISA) in 63 AD patients and compared them with 77 age- and gender-matched non-demented controls. RESULTS: Serum TGF-beta1 levels were not different in AD patients than in controls. Distribution of the allele and genotype frequencies of TGF-beta1 polymorphisms did not differ between AD patients and controls. There was no significant correlation between serum TGF-beta1 levels and TGF-beta1 polymorphisms. CONCLUSION: Serum TGF-beta1 concentration is not a potential biomarker for AD, and TGF-beta1 genetic variants (-800, -509, and +869) are not risk factors for AD.
